JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.